Roth Capital Has Negative Forecast for REVB FY2028 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Stock analysts at Roth Capital cut their FY2028 earnings per share estimates for shares of Revelation Biosciences in a research report issued to clients and investors on Wednesday, December 4th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of $2.03 per share for the year, down from their previous estimate of $2.06. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.80) per share.

Revelation Biosciences Trading Down 3.4 %

NASDAQ REVB opened at $0.45 on Friday. The company has a market capitalization of $1.95 million, a PE ratio of -0.03 and a beta of 0.15. The stock has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $1.28. Revelation Biosciences has a 12 month low of $0.42 and a 12 month high of $25.26.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.